Events & Webinars

Treatment tolerability in mHSPC and nmCRPC

Expert Insights Videos

Description

Discover these expert opinions on the management and treatment of patients prescribed NUBEQA in clinical practice. These two informative videos feature leading oncologists,

Professor Alison Birtle

and Dr. Amar Challapalli
, who provide their valuable perspective on understanding patient goals in mHSPC and nmCRPC, the significance of patient selection and the importance of maintaining quality of life when selecting a treatment for your patients.

Stay informed and enhance your clinical practice with these expert insights:

Listen and learn: Prof. Birtle on the tolerability profile of NUBEQA in mHSPC

NUBEQA Prescribing Information

ARASENS trial. Men with mHSPC. NUBEQA + ADT + docetaxel (n=651) vs. placebo + ADT + docetaxel (n=654). Primary endpoint was OS. The most frequently observed adverse reactions in patients with mHSPC receiving NUBEQA are hypertension, rash, blood bilirubin increased, ALT increased, AST increased (≥1/10). The most common serious adverse reactions in patients receiving darolutamide in combination with docetaxel were febrile neutropenia (6.1%), neutrophil count decreased (2.8%) and pneumonia (2.5%).

Discover more about the ARASENS trial

Listen and learn: Dr. Challapalli on the tolerability profile of NUBEQA in nmCRPC

NUBEQA Prescribing Information

ARAMIS trial. Men with high-risk nmCRPC. NUBEQA + ADT (n=955) vs. placebo + ADT (n=554). Primary endpoint was median metastasis free survival (MFS), secondary endpoint was overall survival (OS). Number of patients with events 148/955 (15.5%) vs. 106/554 (19.1%) with placebo + ADT. Final analysis for OS was conducted after 254 deaths.

The most frequently observed adverse reactions in patients with nmCRPC receiving NUBEQA were fatigue/asthenic conditions, neutrophil count decreased, blood bilirubin increased and AST increased (≥1/10), and rash, pain in the extremity, musculoskeletal pain, fractures, ischaemic heart disease and heart failure (≥1/100).

Discover more about the ARAMIS trial

Speakers

Professor Alison Birtle
Professor Alison Birtle
Prof. Alison Birtle is a Consultant Clinical Oncologist at the Rosemere Cancer Centre, Lancashire Teaching Hospitals, Honorary Clinical Professor in the Faculty of Biology, Medicine & Health at the University of Manchester and Honorary Clinical Professor at The University of Central Lancashire, specialising in the treatment of urological cancers. She is advisor to Macmillan on patient information for prostate, bladder and testicular tumours, Trustee and medical advisor to Fight Bladder Cancer and Secretary to the British Uro-oncology Group. She has been Chair of the NIHR Bladder/renal Research Group, member of ESMO Educational Faculty, and in 2022 joined the EAU Guidelines Group on UTUC and NMIBC.
Prof. Birtle has been Principal Investigator and Chief Investigator on numerous urological clinical trials and in 2018, she was awarded one of the national 70 stars of the NHS award by NHS England and the NHS Confederations and has won numerous prestigious awards including Researcher of the year North West Coast Health & Innovation Awards.
Dr Amarnath Challapalli
Dr Amarnath Challapalli
Dr Amarnath Challapalli is a Consultant Clinical Oncologist and Clinical Director of the Bristol Haematology and Oncology Centre (BHOC), University Hospitals Bristol and Weston NHS Foundation Trust, specialising in the management of urological cancers and non-melanoma skin cancers.
Dr. Challapalli is a Prostate Cancer UK (PCUK) Clinical Champion. He is a clinical expert for the NICE evidence review groups (Sheffield & PenTAG). He is a member of the Clinical Reference Group (CRG) of the National Kidney Cancer Audit (NKCA), representing The Royal College of Radiologists.

ASCO-GU 2023: The DEAR study in nmCRPC

NUBEQA® (darolutamide)

NUBEQA Prescribing Information

PP-NUB-GB-2022, January 2025

PP-NUB-GB-2036 | January 2025

References
1
NUBEQA (darolutamide) Summary of Product Characteristics.
2
Shore ND. Urology. 2015;85(4):717-724.
3
Fizazi K et al. N Engl J Med. 2019;380(13):1235–1246.
4
Saad F, et al. Can Urol Assoc J. 2015;9(3-4):90-96.